Your browser is no longer supported. Please, upgrade your browser.
INmune Bio, Inc.
Index- P/E- EPS (ttm)-1.12 Insider Own40.59% Shs Outstand14.32M Perf Week13.52%
Market Cap254.54M Forward P/E- EPS next Y-2.09 Insider Trans-0.34% Shs Float10.48M Perf Month77.11%
Income-14.60M PEG- EPS next Q-0.34 Inst Own8.90% Short Float9.17% Perf Quarter17.26%
Sales0.01M P/S17064.90 EPS this Y-35.00% Inst Trans55.83% Short Ratio5.57 Perf Half Y94.11%
Book/sh4.44 P/B4.01 EPS next Y-47.20% ROA-33.80% Target Price29.50 Perf Year224.23%
Cash/sh3.17 P/C5.62 EPS next 5Y- ROE-35.30% 52W Range4.50 - 29.99 Perf YTD3.37%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-40.65% Beta-
Dividend %- Quick Ratio22.40 Sales past 5Y- Gross Margin- 52W Low295.56% ATR1.31
Employees5 Current Ratio22.40 Sales Q/Q- Oper. Margin- RSI (14)68.42 Volatility9.04% 10.21%
OptionableYes Debt/Eq0.00 EPS Q/Q-65.10% Profit Margin- Rel Volume1.52 Prev Close18.01
ShortableYes LT Debt/Eq0.00 EarningsMay 05 AMC Payout- Avg Volume172.67K Price17.80
Recom1.70 SMA2024.09% SMA5042.26% SMA20037.50% Volume259,020 Change-1.17%
Apr-21-21Initiated B. Riley Securities Buy $29
Jan-22-21Reiterated Maxim Group Buy $16 → $32
Sep-01-20Initiated BTIG Research Buy $23
Jul-15-20Reiterated H.C. Wainwright Buy $7 → $20
Jun-14-21 04:01PM  
Jun-13-21 10:59PM  
Jun-02-21 09:00AM  
May-24-21 09:00AM  
May-06-21 04:01AM  
May-05-21 04:15PM  
Apr-28-21 09:00AM  
Apr-26-21 09:00AM  
Mar-22-21 09:00AM  
Mar-08-21 09:00AM  
Mar-05-21 07:30PM  
Mar-04-21 04:15PM  
Feb-25-21 09:00AM  
Jan-25-21 01:50AM  
Jan-21-21 03:53PM  
Jan-13-21 08:00AM  
Nov-27-20 10:59AM  
Nov-17-20 10:33AM  
Nov-09-20 07:00AM  
Nov-05-20 04:00PM  
Oct-29-20 08:30AM  
Oct-26-20 07:51AM  
Oct-05-20 09:00AM  
Sep-23-20 06:00AM  
Sep-16-20 07:00AM  
Sep-14-20 07:00AM  
Sep-03-20 09:00AM  
Sep-01-20 09:00AM  
Aug-13-20 09:00AM  
Aug-05-20 04:01PM  
Aug-03-20 07:00AM  
Jul-31-20 07:00AM  
Jul-27-20 07:00AM  
Jul-20-20 04:57PM  
Jul-16-20 09:15AM  
Jul-15-20 04:10PM  
Jul-14-20 04:16PM  
Jul-13-20 04:16PM  
Jul-09-20 09:00AM  
Jun-24-20 05:21AM  
Jun-11-20 09:00AM  
May-19-20 09:00AM  
May-14-20 09:00AM  
May-11-20 09:00AM  
May-06-20 04:20PM  
Apr-28-20 09:00AM  
Apr-23-20 09:00AM  
Apr-22-20 10:55AM  
Apr-20-20 09:00AM  
Mar-16-20 05:35AM  
Mar-11-20 09:00AM  
Mar-05-20 09:00AM  
Feb-27-20 09:00AM  
Feb-10-20 09:08AM  
Jan-29-20 08:25AM  
Jan-02-20 09:00AM  
Dec-17-19 09:00AM  
Dec-02-19 09:00AM  
Nov-26-19 06:00AM  
Nov-25-19 08:05AM  
Nov-19-19 09:00AM  
Nov-08-19 04:00PM  
Oct-21-19 03:00PM  
Oct-17-19 09:00AM  
Oct-08-19 09:00AM  
Sep-24-19 10:20AM  
Sep-23-19 09:03AM  
Sep-20-19 10:02AM  
Sep-17-19 09:05AM  
Sep-12-19 08:30AM  
Sep-05-19 08:33AM  
Sep-04-19 09:06AM  
Aug-21-19 02:25PM  
Aug-13-19 07:25AM  
Aug-12-19 09:01AM  
Aug-08-19 08:30AM  
Aug-06-19 03:40PM  
Aug-05-19 09:01AM  
Aug-01-19 09:01AM  
Jul-25-19 09:01AM  
Jul-03-19 09:01AM  
Jun-27-19 09:03AM  
Jun-11-19 08:30AM  
Jun-10-19 01:35PM  
Jun-04-19 04:45PM  
May-28-19 09:03AM  
May-22-19 10:00AM  
May-16-19 09:04AM  
May-15-19 09:03AM  
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer Alzheimer's disease, and non-alcoholic steatohepatitis. The company intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation in their blood; XPro1595 for the treatment of Alzheimer's disease; LivNate to treat patients with non-alcoholic steatohepatitis; and Quellor for cytokine release syndrome and complications of COVID-19. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in La Jolla, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schroeder Timothy jDirectorJun 14Sale19.0210,000190,200136,667Jun 15 04:09 PM
Schroeder Timothy jDirectorJun 10Sale17.0110,000170,054146,667Jun 14 04:22 PM